157 related articles for article (PubMed ID: 8851613)
1. Penetration of ciprofloxacin and fleroxacin into biliary tract.
Edmiston CE; Suarez EC; Walker AP; Demeure MP; Frantzides CT; Schulte WJ; Wilson SD
Antimicrob Agents Chemother; 1996 Mar; 40(3):787-91. PubMed ID: 8851613
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of oral fleroxacin and ciprofloxacin in plasma and sputum during acute and chronic dosing.
Begg EJ; Robson RA; Saunders DA; Graham GG; Buttimore RC; Neill AM; Town GI
Br J Clin Pharmacol; 2000 Jan; 49(1):32-8. PubMed ID: 10606835
[TBL] [Abstract][Full Text] [Related]
3. The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers.
Hoogkamer JF; Kleinbloesem CH
Drugs; 1995; 49 Suppl 2():346-8. PubMed ID: 8549357
[No Abstract] [Full Text] [Related]
4. Single-dose pharmacokinetic study of ciprofloxacin and fleroxacin in healthy adult Nigerian volunteers.
Chukwuani CM; Coker HA; Oduola AM; Ifudu ND; Sowunmi A
Chemotherapy; 1998; 44(6):369-76. PubMed ID: 9755295
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and biliary concentrations of fleroxacin in cholecystectomized patients.
Hayton WL; Vlahov V; Bacracheva N; Viachki I; Portmann R; Muirhead G; Stoeckel K; Weidekamm E
Antimicrob Agents Chemother; 1990 Dec; 34(12):2375-80. PubMed ID: 2128442
[TBL] [Abstract][Full Text] [Related]
6. Penetration of fleroxacin and ciprofloxacin into skin blister fluid: a comparative study.
Lubowski TJ; Nightingale C; Sweeney K; Quintiliani R; Zhi J
Antimicrob Agents Chemother; 1992 Mar; 36(3):651-5. PubMed ID: 1622179
[TBL] [Abstract][Full Text] [Related]
7. Bioavailability of ciprofloxacin and fleroxacin: results of a preliminary investigation in healthy adult Nigerian male volunteers.
Chukwuani CM; Coker HA; Oduola AM; Sowunmi A; Ifudu ND
Biol Pharm Bull; 2000 Aug; 23(8):968-72. PubMed ID: 10963305
[TBL] [Abstract][Full Text] [Related]
8. Developmental toxicity of fleroxacin and comparative pharmacokinetics of four fluoroquinolones in the cynomolgus macaque (Macaca fascicularis).
Hummler H; Richter WF; Hendrickx AG
Toxicol Appl Pharmacol; 1993 Sep; 122(1):34-45. PubMed ID: 8397453
[TBL] [Abstract][Full Text] [Related]
9. Intestinal elimination of sparfloxacin, fleroxacin, and ciprofloxacin in rats.
Rubinstein E; Dautrey S; Farinoti R; St Julien L; Ramon J; Carbon C
Antimicrob Agents Chemother; 1995 Jan; 39(1):99-102. PubMed ID: 7695338
[TBL] [Abstract][Full Text] [Related]
10. Hepatobiliary kinetics and excretion of ciprofloxacin.
Parry MF; Smego DA; Digiovanni MA
Antimicrob Agents Chemother; 1988 Jul; 32(7):982-5. PubMed ID: 3190199
[TBL] [Abstract][Full Text] [Related]
11. A comparison of the penetration of two quinolones into intra-abdominal abscess.
Tudor RG; Youngs DJ; Yoshioka K; Burdon DW; Keighley MR
Arch Surg; 1988 Dec; 123(12):1487-90. PubMed ID: 3142444
[TBL] [Abstract][Full Text] [Related]
12. Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine.
Kim MK; Nightingale C; Nicolau D
Clin Pharmacokinet; 2003; 42(11):985-96. PubMed ID: 12908854
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics of Ro 23-9424, a dual-action cephalosporin, in animals.
Christenson JG; Chan KK; Cleeland R; Dix-Holzknecht B; Farrish HH; Patel IH; Specian A
Antimicrob Agents Chemother; 1990 Oct; 34(10):1895-900. PubMed ID: 2127171
[TBL] [Abstract][Full Text] [Related]
14. Once-daily fleroxacin versus twice-daily ciprofloxacin in the treatment of complicated urinary tract infections.
Frankenschmidt A; Naber KG; Bischoff W; Kullmann K
J Urol; 1997 Oct; 158(4):1494-9. PubMed ID: 9302150
[TBL] [Abstract][Full Text] [Related]
15. Biliary excretion of ciprofloxacin and piperacillin in the obstructed biliary tract.
van den Hazel SJ; de Vries XH; Speelman P; Dankert J; Tytgat GN; Huibregtse K; van Leeuwen DJ
Antimicrob Agents Chemother; 1996 Nov; 40(11):2658-60. PubMed ID: 8913485
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetics of [18F]fleroxacin in patients with acute exacerbations of chronic bronchitis and complicated urinary tract infection studied by positron emission tomography.
Fischman AJ; Livni E; Babich JW; Alpert NM; Bonab A; Chodosh S; McGovern F; Kamitsuka P; Liu YY; Cleeland R; Prosser BL; Correia JA; Rubin RH
Antimicrob Agents Chemother; 1996 Mar; 40(3):659-64. PubMed ID: 8851589
[TBL] [Abstract][Full Text] [Related]
17. Bactericidal kinetics of various dosages of fleroxacin simulated in bacterial cultures.
Bauernfeind A; Eberlein E; Hörl G
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():81-9. PubMed ID: 3144553
[TBL] [Abstract][Full Text] [Related]
18. Single and multiple dose pharmacokinetics of fleroxacin.
Weidekamm E; Portmann R; Partos C; Dell D
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():145-54. PubMed ID: 3144533
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetics and body fluid penetration of fleroxacin in healthy volunteers.
Sorgel F; Metz R; Naber K; Seelmann R; Muth P
J Antimicrob Chemother; 1988 Oct; 22 Suppl D():155-67. PubMed ID: 3144534
[TBL] [Abstract][Full Text] [Related]
20. Ciprofloxacin biliary disposition in cholecystectomised patients with special references to HPLC and bioassay data.
Jehl F; Adloff M; Monteil H; Brogard JM
Eur J Drug Metab Pharmacokinet; 1987; 12(2):115-22. PubMed ID: 3691576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
